Levosimendan in Europe and China: An Appraisal of Evidence and Context
The calcium sensitiser levosimendan (SIMDAX; Orion Pharma) has been in clinical use for the management of acute heart failure and a range of related syndromes in many countries around the world for two decades. More recently, levosimendan has become available in China. The authors have examined the...
Saved in:
| Main Authors: | Xiangqing Kong, Xinqun Hu, Baotong Hua, Francesco Fedele, Dimitrios Farmakis, Piero Pollesello |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2021-11-01
|
| Series: | European Cardiology Review |
| Online Access: | https://www.ecrjournal.com/articleindex/ecr.2021.41 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan
by: Piergiuseppe Agostoni, et al.
Published: (2019-11-01) -
Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use
by: Zoltán Papp, et al.
Published: (2020-08-01) -
Bibliometric analysis of levosimendan
by: Xian-Shu Zhao, et al.
Published: (2025-02-01) -
Use of Levosimendan in Cardiac Anesthesiology
by: L. A. Krichevsky, et al.
Published: (2011-08-01) -
EVALUATION OF LEVOSIMENDAN EFFICIENCY IN CARDIAC SURGERY
by: I. A. Kozlov, et al.
Published: (2018-01-01)